Abstract Details

Title The Diagnostic Yield of Repetitive Nerve Stimulation in Seropositive vs. Seronegative

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-027

Objective The objective of this study was to assess the impact of clinical, serological, demographic factors on the diagnostic yield of RNS.

Background The low frequency repetitive nerve stimulation (RNS) is commonly used in the diagnosis of myasthenia gravis (MG). The effect of various clinical factors on its diagnostic yield is unknown.

Design/Methods All patients with established the diagnosis of MG and at least one-year follow-up at the hospital were retrospectively analyzed. 65 patients were identified and characterized by their demographic information and Myasthenia Gravis Foundation of America (MGFA) class (I-V). Fishers t-test was used to test association between various clinical factors and the yield of RNS.

Results

34 patients (52%) were male and 31 (48%) were female. 55 (85%) patients identified as white, 8 (12%) as African Americans. The average age of the cohort was 55 (SD=20). 32 (49.2%) patients were in MGFA Class I; 14 (21.5%) were in MGFA class IIa; 13 (20.0%) were in MGFA class IIb; The remaining 6 (9.2%) patients were in MGFA classes IIIa-V. 27 patients were seropositive; 38 patients were seronegative. 11 patients were tested for RNS studies in the inpatient setting; 54 patients were tested in the outpatient setting. Diagnostic yield of RNS was higher for sero-positive patients (20 seropositive, 21 seronegative, p<0.05). Patients with MGFA class III or more also had higher diagnostic yield as compared to earlier classes (p<0.05). Diagnostic yield was the highest for patients with MGFA class III or more tested in an inpatient setting (p<0.05).

Conclusions

Testing done in an inpatient setting, seropositive status, MGFA class III or more are predictors of a positive repetitive stimulation in the diagnosis of myasthenia gravis.

Authors/Disclosures
Tingting Hua PRESENTER	No disclosure on file
	No disclosure on file
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group)	Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��